Dr. Howard Rutman, MD MBA
Dr. Rutman is the Group Vice President and Medical Director of Taro Pharmaceuticals, a multinational, science-driven specialty and generic pharmaceutical company. As Medical Director, he oversees the Phase II and Phase III clinical research program for several novel IND/NDA products and interacts with the FDA on the development and approval process. He also establishes contacts with the scientific and investor community on potential strategic alliances and business development opportunities. Dr. Rutman received his undergraduate education at Harvard, his medical degree from Johns Hopkins and his MBA from Stern-NYU.
He currently serves on the clinical cardiology teaching services of two university medical centers – the Albert Einstein College of Medicine and the Mount Sinai School of Medicine, continuing his 20-year experience of academic teaching and Park Avenue cardiology practice in New York City.
Dr. Steven R. Levine, MD
Dr. Levine is a Professor of Neurology and Director of Cerebrovascular Education Program at the Mount Sinai School of Medicine & Medical Center in New York City. Prior to his arrival in New York, Dr. Levine was the Detroit area principal investigator for the NIH funded NINDS rt-PA Stroke Trial that led to FDA approval of the first treatment for acute ischemic stroke tissue plasminogen activator. Since 1987, Dr. Levine’s research has been NIH funded for the past 11 years and he has trained stroke sub-specialists (fellows). He is the editor of the National Stroke Association’s Stroke-Clinical Updates and serves on the Editorial Boards of Stroke, Clinical Neuropharmacology, and Seminars in Stroke and Cerebrovascular Disease. Dr. Levin brings world class expertise which will aid Elfi-Tech in the development of its non-invasive diagnostic devices as they are progressed through the clinic.
Dr. George Babitsky, MD
Dr. Babitsky has been actively involved in clinical and business development of Glucose and Hemoglobin (Hb) non-invasive medical devices for many years with an advanced medical device company, OrSense. He has organized a number of clinical studies in New York for Hb and Glucose monitoring devices. In addition, Dr. Babitsky maintains a strong network within the medical device industry in the U.S. including companies such as J&J and other major organizations. He is a staunch supporter of developing a non-invasive device targeting the blood anti-coagulation market and brings his unique clinical perspective to the team. In summary, Dr. Babitsky has extensive experience in early stage medical device development and maintains strong business contacts with many potential strategic partners for Elfi-Tech. Dr. Babitsky has practiced medicine in the U.S. for over 20 years and is currently practicing Endocrinology and Internal Medicine in New York City.
